Farheen Shah Khan, MD
Nephrology · Chicago, ILNPI 1164644480
Payments from drug & device makers
Across 121 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$632
- AstraZeneca$456
- Boehringer Ingelheim$405
- Travere Therapeutics, Inc.$149
- Calliditas Therapeutics US Inc.$145
- Lilly USA, LLC$132
- plus $776 from 17 others
What the payments were for
- Food & beverage$2,60597%
- Education$913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 29 | $632 |
| AstraZeneca(2 entities) | 22 | $456 |
| Boehringer Ingelheim | 15 | $405 |
| Travere Therapeutics, Inc. | 9 | $149 |
| Calliditas Therapeutics US Inc. | 6 | $145 |
| Lilly USA, LLC | 5 | $132 |
| Mallinckrodt Hospital Products Inc. | 3 | $92 |
| Vifor Pharma, Inc. | 4 | $79 |
| GSK | 4 | $70 |
| OPKO Pharmaceuticals, LLC | 3 | $69 |
| Akebia Therapeutics Inc | 4 | $67 |
| Novo Nordisk | 3 | $66 |
| Amgen | 2 | $56 |
| Merck | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Lemaitre Vascular, Inc. | 1 | $34 |
| AbbVie | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Novartis | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,696 in reported general payments places this provider in the 70th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 242 | $202,975 |
| KerendiaFinerenone | 88 | $101,918 |
| EliquisApixaban | 265 | $89,184 |
| TradjentaLinagliptin | 142 | $81,324 |
| JardianceEmpagliflozin | 90 | $50,177 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $43,235 |
| JanuviaSitagliptin Phosphate | 70 | $40,692 |
| DapagliflozinDapagliflozin Propanediol | 51 | $25,929 |
| LokelmaSodium Zirconium Cyclosilicate | 29 | $25,833 |
| LinzessLinaclotide | 31 | $20,070 |
| OzempicSemaglutide | 12 | $14,657 |
| TrulicityDulaglutide | 13 | $12,682 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $11,325 |
| Sevelamer Carbonate | 52 | $10,877 |
| EntrestoSacubitril/Valsartan | 42 | $10,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Brilinta | $456 | $237,784295 claims |
| Boehringer IngelheimTradjenta, Jardiance | $405 | $131,501232 claims |
| BayerKerendia | $632 | $101,91888 claims |
| MerckJanuvia | $40 | $40,69270 claims |
| AbbVieLinzess | $33 | $20,07031 claims |
| Novo NordiskOzempic | $66 | $14,65712 claims |
| Lilly USA, LLCTrulicity | $132 | $12,68213 claims |
| NovartisEntresto | $27 | $10,76642 claims |
| GSKBreo Ellipta | $70 | $9,06621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 524 nephrology providers in Illinois.
Other nephrology in Chicago
- Myles WolfChicago$22.4M
- Beatrice ConcepcionChicago$2.6M
- April KennedyChicago$1.8M
- Khaleel SayeedChicago$1.7M
- Tamara IsakovaChicago$763K
- William WhittierChicago$668K
- Arlene ChapmanChicago$505K
- Daniel BatlleChicago$491K
- John FriedewaldChicago$472K
- Cybele GhosseinChicago$398K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.